spacer
home > ict > winter 2018 > clinical acceleration
PUBLICATIONS
International Clinical Trials

Clinical Acceleration

The development of therapies for central nervous system (CNS) diseases has lagged behind other areas, despite these diseases affecting over one billion individuals worldwide (1). As the population ages, the incidence of disorders like Alzheimerís disease, Parkinsonís disease, and stroke are expected to rise, further increasing their impact on society.

CNS drugs take longer on average than drugs in other therapeutic areas and are half as likely to reach the market (2). Development programmes in CNS are lengthier and more complex for several reasons; the most consequential of which include the heterogeneous nature of CNS disorders, suboptimal preclinical models, bloodbrain- barrier penetration impediments, and challenges in recruitment and retention of patients. Furthermore, overly lengthy development timelines can shorten the initial investment time span of a new compound. Changing or unestablished regulatory requirements can halt drug development if they occur too late in the process for the clinical development plan to be adapted. The pharmaceutical industry needs new strategies to increase the success rate of CNS therapy development and approval.

Over the past few years, there has been a trend for pharma companies to target orphan indications, essentially utilising rare diseases to obtain the initial clinical proof-of-concept and approval for a compound. This approach offers advantages in a competitive landscape, minimising risk and potentially availing new or repurposed drugs to eventually be studied in broader indications. With the growing number of gene therapies targeting subpopulations in diseases like muscular dystrophy, Huntington's disease, Friedreich's ataxia, etc, studies in smaller homogenous CNS populations are often appropriate.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Kemi Olugemo is a Neurologist and Senior Medical Director at PAREXEL. She received her bachelorís degree from the University of Massachusetts, US, and her MD from the University of Maryland School of Medicine, US. Kemi initially joined PAREXEL International in September 2011 as a Clinical Research Physician. She served as the Principal Investigator or Sub-Investigator for over 50 studies spanning from Phase 1-4 in several therapeutic areas, including CNS, oncology, endocrine, cardiovascular, and infectious disease. Kemi re-joined PAREXEL International as Medical Director in June 2014. Her current responsibilities include medical monitoring; consulting in clinical drug development from pre-clinical through post-marketing, support for protocol development, regulatory submissions, and manuscript development; training on therapeutic areas, specific disease states, adverse events assessment/ management; and addressing medical and scientific questions for PAREXEL. Kemi is certified by the American Board of Psychiatry and Neurology
spacer
Dr Kemi Olugemo
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Acquires UK-based Clinical Trials Laboratory Services

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Clinical Trials Laboratory Services (CTLS), a donor center and laboratory based in London, UK. CTLS provides dedicated high-quality serum, plasma and blood collection services. It also offers full-service cell processing capabilities on site.
More info >>

White Papers

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology

European Society for Medical Oncology (ESMO)

  The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries.
More info >>

 
Industry Events

Synthetic Biology Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its Synthetic Biology Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement